Vaccine responsiveness in the elderly: Best practice for the clinic

Expert Review of Vaccines

Volumn 13, Issue 7, 2014, Pages 885-894

  Aspinall, Richard ^a   Lang, Pierre Olivier ^a,b  

^a CRANFIELD UNIVERSITY   (United Kingdom)

^b Nescens Centre of Preventive Medicine   (Switzerland)

Author keywords

aging; immune profiling; immunity; immunosenescence; vaccination

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; PNEUMOCOCCUS VACCINE; VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; VARICELLA ZOSTER VACCINE;

CHILDHOOD DISEASE; CLINICAL PRACTICE; COMMUNICABLE DISEASE; DIPHTHERIA; DISABILITY; DRUG EFFICACY; ELDERLY CARE; GOVERNMENT; HEALTH CARE POLICY; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; INFLUENZA; PERTUSSIS; PNEUMOCOCCAL INFECTION; POSTHERPETIC NEURALGIA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; REVIEW; TETANUS PROPHYLAXIS; TRAVEL; VACCINATION; AGE; AGED; AGING; ANTIBODY PRODUCTION; IMMUNOLOGY; INFLUENZA VIRUS A; INFLUENZA, HUMAN; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTIBODY FORMATION; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INFLUENZAVIRUS A; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES;

EID: 84902327034     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.924403     Document Type: Review

References (87)

1. Suzman R, Beard J. Global health and aging. Available from: www.nia.nih.gov/sites/default/files/niawho-report-booklet-oct-2011-a4-1-12-12-5. pdf
2. McElhaney JE. Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines. Aging health 2008; 4(6):603-13
3. Collerton J, Davies K, Jagger C, et al. Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study. BMJ 2009;339:b4904.
4. Aspinall R, Lang PO. The Avalanche is coming. and just now it's starting to snow. Front Immunol 2013;4:165
5. Gautret P, Gaudart J, Leder K, et al. Travel-associated illness in older adults (>60 y). J Travel Med 2012;19(3):169-77
6. Marti F, Steffen R, Mutsch M. Influenza vaccine: a travelers' vaccine? Expert Rev Vaccines 2008;7(5):679-87 (Pubitemid 351890333)
7. Jones KE, Patel NG, Levy MA, et al. Global trends in emerging infectious diseases. Nature 2008;451(7181):990-3 (Pubitemid 351301726)
8. Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001;344(24):1807-14 (Pubitemid 32538693)
9. Plotkin SA. Vaccines: past, present and future. Nat Med 2005;11(Suppl 4):S5-11
10. Moxon ER, Siegrist CA. The next decade of vaccines: societal and scientific challenges. Lancet 2011;378(9788):348-59
11. Moxon ER, Das P, Greenwood B, et al. A call to action for the new decade of vaccines. Lancet 2011;378(9788):298-302
12. Nabel GJ. Designing tomorrow's vaccines. N Engl J Med 2013;368(6):551-60
13. Michel JP, Lang PO. Promoting life course vaccination. Rejuvenation Res 2011;14(1): 75-81
14. Dowdle WR, Cochi SL. The principles and feasibility of disease eradication. Vaccine 2011;29(Suppl 4):D70-3
15. Lang PO, Govind S, Bokum AT, et al. Immune senescence and vaccination in the elderly. Curr Top Med Chem 2013;13(20): 2541-50
16. Shaw AC, Panda A, Joshi SR, et al. Dysregulation of human Toll-like receptor function in aging. Ageing Res Rev 2011; 10(3):346-53
17. Panda A, Qian F, Mohanty S, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010;184(5):2518-27
18. Saurwein-Teissl M, Lung TL, Marx F, et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 2002; 168(11):5893-9 (Pubitemid 34556178)
19. Sasaki S, Sullivan M, Narvaez CF, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest 2011;121(8):3109-19.
20. Ademokun A, Wu YC, Martin V, et al. Vaccination-induced changes in human B-cell repertoire and pneumococcal IgM and IgA antibody at different ages. Aging Cell 2011;10(6):922-30
21. Yager EJ, Ahmed M, Lanzer K, et al. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J Exp Med 2008;205(3):711-23 (Pubitemid 351439315)
22. Aspinall R, Andrew D. Thymic atrophy in the mouse is a soluble problem of the thymic environment. Vaccine 2000;18(16): 1629-37 (Pubitemid 30109520)
23. Buffa S, Bulati M, Pellicano M, et al. B cell immunosenescence: different features of naive and memory B cells in elderly. Biogerontology 2011;12(5):473-83
24. Sapey E, Greenwood H, Walton G, et al. Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. Blood 2014;123(2):239-48
25. Chidrawar SM, Khan N, Chan YL, et al. Ageing is associated with a decline in peripheral blood CD56bright NK cells. Immun Ageing 2006;3:10
26. Laurent M, Bastuji-Garin S, Plonquet A, et al. Interrelations of immunological parameters, nutrition, and healthcare-associated infections: Prospective study in elderly in-patients. Clin Nutr 2014. [Epub ahead of print]
27. Fulop T, Larbi A, Witkowski JM, et al. Aging, frailty and age-related diseases. Biogerontology 2010;11(5):547-63
28. NHS. Vaccine Choices. Available from: www.nhs.uk/chq/Pages/1039.aspx? CategoryID=62
29. Vaccine choices for seniors. Available from: www.vaccines.gov/who-and- when/seniors/
30. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med 2008;121(4):258-64 (Pubitemid 351417852)
31. Clements KM, Meier G, McGarry LJ, et al. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother 2014;10:5
32. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003;21(16): 1776-9 (Pubitemid 36398372)
33. Immunisation against infectious disease. The Green Book. Available from: www.gov. uk/government/collections/immunisationagainst-infectious-disease-the- green-book
34. Eichelberger M, Golding H, Hess M, et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development. Bethesda, Maryland, US, December 10-11, 2007. Vaccine 2008; 26(34):4299-303
35. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979;35(1):69-75 (Pubitemid 9096975)
36. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004; 103(1-2):133-8 (Pubitemid 38649072)
37. Lang PO, Govind S, Mitchell WA, et al. Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience. Ageing Res Rev 2011;10(3):389-95
38. Monto AS, Ansaldi F, Aspinall R, et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 2009;27(37):5043-53
39. Remarque EJ, de Jong JM, van der Klis RJ, et al. Dose-dependent antibody response to influenza H1N1 vaccine component in elderly nursing home patients. Exp Gerontol 1999;34(1):109-15 (Pubitemid 29085072)
40. Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008;198(5):650-8
41. Mannino S, Villa M, Apolone G, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012;176(6):527-33
42. Chen WH, Cross AS, Edelman R, et al. Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. Vaccine 2011;29(16):2865-73
43. Song JY, Cheong HJ, Noh JY, et al. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine. J Med Virol 2013; 85(9):1591-7
44. Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009;27(52): 7304-12
45. Lavallee P, Perchaud V, Gautier-Bertrand M, et al. Association between influenza vaccination and reduced risk of brain infarction. Stroke 2002;33(2):513-18 (Pubitemid 34123398)
46. Naghavi M, Barlas Z, Siadaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000;102(25): 3039-45
47. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003;348(14):1322-32 (Pubitemid 36384099)
48. Assaad U, El-Masri I, Porhomayon J, El-Solh AA. Pneumonia immunization in older adults: review of vaccine effectiveness and strategies. Clin Interv Aging 2012;7: 453-61
49. WHO. Recommendtions for the production and control of pneumococcal conjugate vaccines. Available from: www.who.int/entity/biologicals/publications/ en/Pneumococcal%20Conjugate% 20Vaccines- Recomm%20for%20the%20production%20&%20control%20of-ECBS%2054th%2017- 21%20Nov%202003.pdf
50. Hammitt LL, Bulkow LR, Singleton RJ, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011;29(12):2287-95
51. Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 2008;26(43):5521-6
52. JCVI. Statement on the discontinuation of the routein pneumoccoal vaccination programme. Available from: http://webarchive.nationalarchives.gov. uk/+/www.dh.gov.uk/ab/jcvi/dh-094744
53. JCVI. Updated statement on the routine pneumoccoal vaccination programme for adults aged 65 and over. Available from: http://webarchive.nationalarchives. gov.uk/+/www.dh.gov.uk/ab/jcvi/dh-094744 2011
54. Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013;31(35): 3577-84
55. Musher DM, Manoff SB, McFetridge RD, et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011;7(9):919-28
56. Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013; 31(35):3585-93
57. Lang PO, Michel JP. Herpes zoster vaccine: what are the potential benefits for the ageing and older adults? Eur Geriatr Med 2011;2:134-9
58. van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009;27(9):1454-67
59. Lang PO. Herpes zoster: the associated burden and its prevention. Geriatr Psychol Neuropsychiatr Vieil 2011;9(4):391-7
60. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol 2012;24(4):494-500
61. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008;197(6):825-35 (Pubitemid 351417005)
62. Eilers R, Krabbe PF, van Essen TG, et al. Assessment of vaccine candidates for persons aged 50 and older: a review. BMC Geriatr 2013;13:32
63. NHS. Shingles Vaccination. Available from: www.nhs.uk/Conditions/ vaccinations/Pages/shingles-vaccination.aspx
64. Tseng HF, Smith N, Sy LS, Jacobsen SJ. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 2011;29(20):3628-32
65. Oxman MN, Levin MJ; Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008;197(Suppl 2):S228-36 (Pubitemid 351590176)
66. WHO. Tetanus. Available from: http://www.who.int/biologicals/vaccines/ tetanus/en/
67. WHO. Diptheria. Available from: http://www.who.int/biologicals/vaccines/ diphtheria/en/
68. WHO. Acellular Pertussis Vaccines. Available from: http://www.who.int/ biologicals/areas/vaccines/apertussis/en/
69. McQuillan GM, Kruszon-Moran D, Deforest A, et al. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 2002;136(9):660-6 (Pubitemid 34462678)
70. CDC. Tetanus surveillance-United States, 2001-2008. MMWR Morb Mortal Wkly Rep 2011;60(12):365-9
71. van Panhuis WG, Grefenstette J, Jung SY, et al. Contagious diseases in the United States from 1888 to the present. N Engl J Med 2013;369(22):2152-8
72. Zepp F, Heininger U, Mertsola J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011;11(7):557-70
73. McGarry LJ, Krishnarajah G, Hill G, et al. Cost-effectiveness of Tdap vaccination of adults aged ‡65 years in the prevention of pertussis in the US: a dynamic model of disease transmission. PloS One 2014;9(1): e72723
74. Weinberger B, Schirmer M, Matteucci Gothe R, et al. Recall responses to tetanus and diphtheria vaccination are frequently insufficient in elderly persons. PloS one 2013;8(12):e82967
75. Ward JI, Cherry JD, Chang SJ, et al. Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis 2006;43(2):151-7
76. Van Damme P, McIntyre P, Grimprel E, et al. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix((R))) in adults 55 years of age and over: a sub-analysis of four trials. Vaccine 2011;29(35):5932-9
77. Alon D, Shitrit P, Chowers M. Risk behaviors and spectrum of diseases among elderly travelers: a comparison of younger and older adults. J Travel Med 2010;17(4): 250-5
78. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis 2006;6:130
79. Leder K, Weller PF, Wilson ME. Travel vaccines and elderly persons: review of vaccines available in the United States. Clin Infect Dis 2001;33(9):1553-66 (Pubitemid 34246152)
80. Looney RJ, Hasan MS, Coffin D, et al. Hepatitis B immunization of healthy elderly adults: relationship between naive CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J Clin Immunol 2001;21(1):30-6 (Pubitemid 32284951)
81. Roukens AH, Soonawala D, Joosten SA, et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PloS One 2011;6(12):e27753
82. McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176(10):6333-9
83. Hirokawa K, Utsuyama M, Ishikawa T, et al. Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells. Mech Ageing Dev 2009;130(1-2):86-91
84. Wikby A, Ferguson F, Forsey R, et al. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci 2005;60(5): 556-65. (Pubitemid 40847916)
85. Mitchell WA, Lang PO, Aspinall R. Tracing thymic output in older individuals. Clin Exp Immunol 2010;161(3):497-503
86. Shen-Orr SS, Furman D. Variability in the immune system: of vaccine responses and immune states. Curr Opin Immunol 2013;25(4):542-7.
87. Furman D, Jojic V, Kidd B, et al. Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol 2013;9:659